On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

Holiday whiplash over CTA enforcement, Nvidia stock pops on CES keynote, weight loss drugs drive healthcare costs up.

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

Eli Lilly shares rose before the bell, after the FDA approved Zepbound to treat sleep apnea. Rival obesity drugmaker Novo Nordisk gained, after sinking Friday on disappointing trial results.